[go: up one dir, main page]

AR032596A1 - Formulacion en granulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1piperazinil] dibenzo(b,f) (1,4)tiazepina, proceso para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades del sistema nervioso, conjunto de elementos (kit) y sachet que la comprenden - Google Patents

Formulacion en granulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1piperazinil] dibenzo(b,f) (1,4)tiazepina, proceso para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades del sistema nervioso, conjunto de elementos (kit) y sachet que la comprenden

Info

Publication number
AR032596A1
AR032596A1 ARP000104954A ARP000104954A AR032596A1 AR 032596 A1 AR032596 A1 AR 032596A1 AR P000104954 A ARP000104954 A AR P000104954A AR P000104954 A ARP000104954 A AR P000104954A AR 032596 A1 AR032596 A1 AR 032596A1
Authority
AR
Argentina
Prior art keywords
formulation
granules
dibenzo
sachet
kit
Prior art date
Application number
ARP000104954A
Other languages
English (en)
Inventor
Daniel Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR032596A1 publication Critical patent/AR032596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Una formulacion en gránulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1 piperazinil]dibenzo [b,f][1,4] tiazepina o una sal farmacéuticamente aceptable de la misma y un aglutinante libremente soluble o muy soluble en agua, en donde los gránulos tienen un rango de densidad promedio de 0,15 g/cm3 a 0,60 g/cm3 y un rango de densidad de compactacion de 0,20 g/cm3 a 0,70 g/cm3 y el 80% de los gránulos están dentro del rango de tamano de 75 a 850 micrones, así como su preparacion y su uso en la fabricacion de medicamentos. Un conjunto de elementos (kit) y un sachet que comprenden dicha formulacion. Esta formulacion es util para tratar enfermedades del sistema nervioso central tales como condiciones psicoticas que incluyen la esquizofrenia.
ARP000104954A 1999-09-21 2000-09-21 Formulacion en granulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1piperazinil] dibenzo(b,f) (1,4)tiazepina, proceso para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades del sistema nervioso, conjunto de elementos (kit) y sachet que la comprenden AR032596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation

Publications (1)

Publication Number Publication Date
AR032596A1 true AR032596A1 (es) 2003-11-19

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104954A AR032596A1 (es) 1999-09-21 2000-09-21 Formulacion en granulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1piperazinil] dibenzo(b,f) (1,4)tiazepina, proceso para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades del sistema nervioso, conjunto de elementos (kit) y sachet que la comprenden

Country Status (37)

Country Link
US (3) US6599897B1 (es)
EP (1) EP1218009B1 (es)
JP (1) JP2003509461A (es)
KR (1) KR100748823B1 (es)
CN (3) CN1188130C (es)
AR (1) AR032596A1 (es)
AT (1) ATE288272T1 (es)
AU (1) AU776292B2 (es)
BG (1) BG65469B1 (es)
BR (1) BR0014107A (es)
CA (1) CA2383131A1 (es)
CO (1) CO5180585A1 (es)
CZ (1) CZ301585B6 (es)
DE (1) DE60017923T2 (es)
DK (1) DK1218009T3 (es)
EE (1) EE200200150A (es)
EG (1) EG24226A (es)
ES (1) ES2235941T3 (es)
GB (2) GB9922271D0 (es)
HK (1) HK1047706B (es)
HU (1) HUP0203531A3 (es)
IL (2) IL148440A0 (es)
IS (1) IS2139B (es)
MX (1) MXPA02002627A (es)
MY (1) MY130208A (es)
NO (1) NO320908B1 (es)
NZ (1) NZ517549A (es)
PL (1) PL198824B1 (es)
PT (1) PT1218009E (es)
RU (1) RU2256453C2 (es)
SI (1) SI1218009T1 (es)
SK (1) SK286884B6 (es)
TR (1) TR200200716T2 (es)
TW (1) TWI226832B (es)
UA (1) UA73529C2 (es)
WO (1) WO2001021179A1 (es)
ZA (1) ZA200201709B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
EP1448169A1 (en) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
EP1879874A2 (en) * 2005-04-21 2008-01-23 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
JP2009536665A (ja) * 2006-05-09 2009-10-15 アストラゼネカ・アクチエボラーグ （２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの新規な塩形態
US20090324717A1 (en) * 2006-07-28 2009-12-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
US20080085888A1 (en) * 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
US8623861B2 (en) * 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
DE602007009036D1 (de) * 2007-02-14 2010-10-21 Lesvi Laboratorios Sl Pharmazeutische Zusammensetzungen mit Quetiapinfumarat
AU2009219286B2 (en) * 2008-02-27 2012-02-09 Intercontinental Great Brands Llc Multi-region confectionery
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US20110183963A1 (en) 2009-12-31 2011-07-28 Travis Mickle Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same
LT2544536T (lt) 2010-03-11 2019-02-25 Kempharm, Inc. Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas
WO2011146009A1 (en) 2010-05-20 2011-11-24 Targacept Inc. New process for the preparation of aryl substituted olefinic amines
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
KR20230029605A (ko) * 2020-04-29 2023-03-03 스테판 컴파니 아민, 양성자화 아민 또는 사차 암모늄 화합물을 함유하는 고형 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
EP0416773B1 (en) * 1989-08-31 1993-03-03 Takeda Chemical Industries, Ltd. Vitamin b12 composition
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
BR9307387A (pt) * 1992-11-09 1999-08-31 Boots Co Plc Agentes terapêuticos
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
EE200200150A (et) 2003-04-15
PT1218009E (pt) 2005-05-31
IL148440A0 (en) 2002-09-12
CZ2002974A3 (cs) 2002-06-12
BR0014107A (pt) 2002-08-20
CN1188130C (zh) 2005-02-09
DK1218009T3 (da) 2005-05-09
GB9922271D0 (en) 1999-11-17
IS2139B (is) 2006-08-15
CO5180585A1 (es) 2002-07-30
US20060159768A1 (en) 2006-07-20
KR100748823B1 (ko) 2007-08-13
GB0021406D0 (en) 2000-10-18
BG65469B1 (bg) 2008-09-30
EP1218009B1 (en) 2005-02-02
NO20021394L (no) 2002-03-20
NZ517549A (en) 2003-10-31
PL198824B1 (pl) 2008-07-31
DE60017923T2 (de) 2006-01-12
ZA200201709B (en) 2003-05-28
EG24226A (en) 2008-11-10
CN1899288A (zh) 2007-01-24
MXPA02002627A (es) 2002-07-30
TR200200716T2 (tr) 2002-06-21
US7022692B2 (en) 2006-04-04
HUP0203531A2 (hu) 2003-02-28
IL148440A (en) 2007-07-04
ES2235941T3 (es) 2005-07-16
SI1218009T1 (en) 2005-06-30
DE60017923D1 (de) 2005-03-10
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
MY130208A (en) 2007-06-29
CA2383131A1 (en) 2001-03-29
CZ301585B6 (cs) 2010-04-21
US6599897B1 (en) 2003-07-29
HK1047706B (en) 2005-06-10
PL357369A1 (en) 2004-07-26
CN1331472C (zh) 2007-08-15
ATE288272T1 (de) 2005-02-15
HK1047706A1 (en) 2003-03-07
IS6308A (is) 2002-03-19
TWI226832B (en) 2005-01-21
CN1374867A (zh) 2002-10-16
BG106509A (en) 2002-12-29
WO2001021179A1 (en) 2001-03-29
SK286884B6 (sk) 2009-07-06
JP2003509461A (ja) 2003-03-11
RU2256453C2 (ru) 2005-07-20
SK3722002A3 (en) 2002-07-02
UA73529C2 (uk) 2005-08-15
NO320908B1 (no) 2006-02-13
HUP0203531A3 (en) 2004-12-28
US20040228914A1 (en) 2004-11-18
AU776292B2 (en) 2004-09-02
EP1218009A1 (en) 2002-07-03
KR20020033186A (ko) 2002-05-04
NO20021394D0 (no) 2002-03-20

Similar Documents

Publication Publication Date Title
AR032596A1 (es) Formulacion en granulos que incluye 11-[4-[2-(2-hidroxietoxi)etil]-1piperazinil] dibenzo(b,f) (1,4)tiazepina, proceso para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades del sistema nervioso, conjunto de elementos (kit) y sachet que la comprenden
ES2611314T3 (es) Composiciones y procedimientos para usar (R)-pramipexol
ES2250434T3 (es) Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores.
RU2002110456A (ru) Гранулированная композиция кветиапина
AU2002218467B2 (en) Anti-proliferative drugs
ES2182079T3 (es) Composiciones farmaceuticas de liberacion sostenida que contienen un derivado de dibenzotiazepina.
BR9809453A (pt) Composição de suprimento de medicamento para a liberação controlada de um ingrediente ativo dentro do meio-ambiente do estÈmago, uso da mesma, formulação farmacêutica, processo para obter gastrorretenção, para o tratamento ou profilaxia de uma doença, para melhorar a absorção gastrointestinal de medicamentos, e para a preparação de uma composição, e, estojo de partes para uso no tratamento de infecção por h. pylori.
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
BRPI0411986A (pt) forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica
PL354264A1 (en) Delayed-action form of administration containing tramadol saccharinate
IT8919867A0 (it) Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
JP2003509461A5 (es)
BR9906772A (pt) Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular
JP2004534066A5 (es)
AU4008699A (en) Combination therapy for treatment of refractory depression
UY26919A1 (es) Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1
BR0107493A (pt) Substâncias para uso no tratamento de psorìase
HUP0201280A3 (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
BR0112839A (pt) Composição de eletriptano em partìculas
ES2315159A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina.
EA011215B1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту, плавающая капсула
CA2240836A1 (en) Method for treating dermatitis
JP2003522112A5 (es)
ES2332225T3 (es) Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
EP0916621A3 (en) Water having a superior ability to disperse oil and fats

Legal Events

Date Code Title Description
FB Suspension of granting procedure